In 2014, MAPS spun out a separate division to direct study and prepare for an eventual FDA application, which it submitted at the conclusion of very last year. In early 2024, that offshoot was renamed Lykos Therapeutics. Expertise heightened creativity, unlock profound insights, and find out a ne